Table 1. Baseline Demographics by CrCl category.
CrCl Category | <30 | 30-44 | 45-59 | 60-89 | ≥90 | Overall |
---|---|---|---|---|---|---|
n | 510 | 8409 | 15477 | 28891 | 18277 | 71683 |
Female | 335 (65.7%) | 4721 (56.1%) | 7118 (46.0%) | 10068 (34.8%) | 4425 (24.2%) | 26715 (37.3%) |
Age | 80.2 (6.8) | 78.5 (6.6) | 75.3 (6.8) | 70.6 (7.7) | 62.6 (8.7) | 70.6 (9.4) |
CrCl | 26.6 (3.0) | 38.7 (4.1) | 52.7 (4.3) | 73.5 (8.5) | 116.1 (26.7) | 75.5 (30.5) |
BMI | 23.6 (4.4) | 25.2 (4.4) | 26.7 (4.4) | 28.9 (4.7) | 33.6 (6.4) | 29.2 (5.9) |
Weight | 59.9 (13.3) | 66.3 (13.3) | 72.9 (13.6) | 82.5 (14.7) | 101.5 (20.3) | 83.2 (20.0) |
Smoking | 190 (37.3%) | 2984 (35.5%) | 6104 (39.4%) | 12659 (43.8%) | 9283 (50.8%) | 31265 (43.6%) |
Diabetes | 129 (25.3%) | 2118 (25.2%) | 4212 (27.2%) | 8607 (29.8%) | 6996 (38.3%) | 22087 (30.8%) |
Stroke | 129 (25.3%) | 2517 (29.9%) | 4737 (30.6%) | 8376 (29.0%) | 4361 (23.9%) | 20147 (28.1%) |
Prior VKA Use | 310 (60.8%) | 5433 (64.6%) | 10328 (66.7%) | 19698 (68.2%) | 13056 (71.4%) | 48892 (68.2%) |
Antiplatelet Use | 196 (38.4%) | 3168 (37.7%) | 5711 (36.9%) | 10142 (35.1%) | 6213 (34.0%) | 25464 (35.5%) |
CHA2DS2-VASc | 4.9 (1.4) | 4.8 (1.4) | 4.5 (1.4) | 3.9 (1.5) | 3.2 (1.4) | 4.0 (1.5) |
AF type | ||||||
Paroxysmal | 89 (17.5%) | 1880 (22.4%) | 3574 (23.1%) | 6870 (23.8%) | 4174 (22.8%) | 16609 (23.2%) |
Persistent/Permanent | 421 (82.5%) | 6526 (77.6%) | 11903 (76.9%) | 22015 (76.2%) | 14098 (77.1%) | 55059 (76.8%) |
Coronary Disease | 201 (39.4%) | 2753 (32.7%) | 5037 (32.5%) | 9137 (31.6%) | 5513 (30.2%) | 22674 (31.6%) |
HTN | 444 (87.1%) | 7285 (86.6%) | 13465 (87.0%) | 25191 (87.2%) | 16380 (89.6%) | 62863 (87.7%) |
Heart Failure | 271 (53.1%) | 4107 (48.8%) | 6884 (44.5%) | 12750 (44.1%) | 9231 (50.5%) | 33276 (46.4%) |
Prior GIB | 23 (4.5%) | 320 (3.8%) | 506 (3.3%) | 750 (2.6%) | 429 (2.3%) | 2030 (2.8%) |
Prior Non-GIB | 55 (10.8%) | 500 (5.9%) | 861 (5.6%) | 1517 (5.3%) | 1049 (5.7%) | 3989 (5.6%) |